Breaking News
January 24, 2018 - Study illustrates role of specific antibodies in protection against influenza
January 24, 2018 - Curcumin could provide meaningful cognitive benefits, study suggests
January 24, 2018 - Tenax Therapeutics Announces Plan to Develop Levosimendan for a Pulmonary Hypertension Indication with No FDA Approved Therapies
January 24, 2018 - EndoBreak: Obesity in 2018; Diabetes Risks in Pregnancy
January 24, 2018 - Recommendations to improve the quality of ultrasound imaging in obstetrics and gynecology
January 24, 2018 - Sensory feedback facilitates enhanced brainwave control of portable hand-exoskeleton
January 24, 2018 - Innovative system helps medical staff to accurately evaluate patients’ risk of falling
January 24, 2018 - Porvair Sciences to showcase microplate and chromatography products at Analytica 2018
January 24, 2018 - Children with cochlear implant learn words faster than kids with normal hearing
January 24, 2018 - Ionis’ Inotersen NDA Accepted for Priority Review by the FDA
January 24, 2018 - Abuse-Deterrent Opioid No Help in Australia
January 24, 2018 - Maternal mortality rates are on the rise, but more accurate estimates are needed
January 24, 2018 - New essential oil inhaler facilitates pain management
January 24, 2018 - USPSTF: Insufficient Evidence to Screen Kids for Scoliosis
January 24, 2018 - Team develops method to identify seizure-causing regions in the brain
January 24, 2018 - New report takes comprehensive look at health effects of e-cigarettes
January 24, 2018 - Researchers develop new indicator for assessing active aging
January 24, 2018 - Research highlights decreasing trend in traditional hysterectomy
January 24, 2018 - Computer-based speech analysis has potential to improve prediction of psychosis
January 24, 2018 - New family of FFPE reagent kits launched by Beckman Coulter Life Sciences
January 24, 2018 - Researchers use epigenetic signatures to advance diagnosis for neurodevelopmental disorders
January 24, 2018 - EPI report reveals air quality as major environmental threat to public health
January 23, 2018 - How to Fight the Flu This Season
January 23, 2018 - Mixed Data for Fatty Acid Intake and Glaucoma
January 23, 2018 - The brains of jazz and classical pianists work differently
January 23, 2018 - Scientists identify protein biomarkers to track patients with Hutchinson-Gilford progeria syndrome
January 23, 2018 - Exercise could extend the life expectancy of breast cancer survivors, study states
January 23, 2018 - Researchers show association between microbiome and cancer-related blood infections
January 23, 2018 - Cancer.com Site Sat Dormant for 10 Years. Now It’s Live Again.
January 23, 2018 - FDA’s program to speed up drug approval shaved nearly a year off the process
January 23, 2018 - Study reveals key challenges and frustrations associated with current RTSM/IRT solutions
January 23, 2018 - Researchers unravel function of protein ‘smallish’
January 23, 2018 - Infants born in withdrawal due to opioid exposure in utero show abnormalities
January 23, 2018 - Researchers block common siren call of glioblastoma and metastatic breast cancer
January 23, 2018 - FDA Accepts New Drug Applications for Merck’s Doravirine, the Company’s Investigational Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), for Treatment of HIV-1 Infection
January 23, 2018 - Six Concerns About Practice Consolidation
January 23, 2018 - How Alzheimer’s Changes the Brain
January 23, 2018 - Pharmaceutical stirs outrage over price hike for brain tumor drug
January 23, 2018 - University under fire for off-the-grid herpes vaccine experiments
January 23, 2018 - Gastric environment permanently changes in the presence of Helicobacter pylori infection
January 23, 2018 - Scientists take tissue-engineering approach to improve healing related to skeletal system
January 23, 2018 - Consumption of dietary fiber can prevent obesity and metabolic syndrome, study shows
January 23, 2018 - FDA Alert: Multiple Drug Products by Flawless Beauty: Recall
January 23, 2018 - Rhymes with Amyloid: That’s Improbable!
January 23, 2018 - CLCN2-related leukoencephalopathy – Genetics Home Reference
January 23, 2018 - Can road salt and other pollutants disrupt our circadian rhythms?
January 23, 2018 - ‘Depression literacy’ program encourages many teens to seek adult help
January 23, 2018 - New initiative seeks to transform the way people live with dementia
January 23, 2018 - Isosec introduces first Virtual Smartcard for NHS Trusts and clinicians
January 23, 2018 - New report reveals rapid growth in Vietnam pharmaceutical market
January 23, 2018 - Obamacare Led to Rise in Breast Cancer Screening
January 23, 2018 - Bariatric Tx Bests Usual Care for Long-Term Health
January 23, 2018 - Keep Your Dogs and Cats Safe From Holiday Hazards
January 23, 2018 - New AI technology significantly improves human kidney analysis
January 23, 2018 - In Trump’s first year, anti-abortion forces make strides despite setbacks
January 23, 2018 - Small PFS Bump in Gastric/GEJ Cancer
January 23, 2018 - Defending against environmental stressors may shorten lifespan
January 23, 2018 - Researchers create cavitation bubbles to remove dental plaque
January 23, 2018 - Discovery offers fresh perspective on how the brain keeps its balance
January 23, 2018 - Opioid exposure linked to physical abnormalities in newborns
January 23, 2018 - Study identifies genes involved in latent asymptomatic state of breast cancer metastases
January 23, 2018 - Kala Pharmaceuticals Announces New Drug Application for Inveltys (KPI-121 1%) Has Been Accepted for Review by the U.S. Food and Drug Administration
January 23, 2018 - Closer Look at Household Contacts Finds More TB Cases
January 23, 2018 - Type 1 IFNs may mediate Zika pregnancy complications
January 23, 2018 - Anti-inflammatory pill could help make vaccines more effective for the elderly
January 23, 2018 - New discovery sheds light on iron-restricted anemia that causes fatigue in millions
January 23, 2018 - BMG LABTECH’s Australian office celebrates 20 years of innovation and growth in APAC region
January 23, 2018 - FDA Alert: Basic Drugs Brand of Senna Laxative by Magno-Humphries Laboratories: Recall
January 23, 2018 - Chronic Opioid Use High Among IBD Patients
January 23, 2018 - New long-acting, less-toxic HIV drug suppresses virus in humanized mice
January 23, 2018 - Findings provide better understanding of cognitive inflexibility in Fragile X Syndrome
January 23, 2018 - Powerful anti-oxidant can stop progression of fatty liver disease in young mice
January 23, 2018 - Marijuana use does not lower probability of conception, study shows
January 23, 2018 - Study shows value of occupational therapy in the lives of young adults with diabetes
January 23, 2018 - Chinese researchers develop multifunctional vehicle to transport gene therapeutics
January 23, 2018 - Researchers seek to understand effect of very low birth weight on the brain
January 23, 2018 - Be a Savvy Supermarket Shopper
January 23, 2018 - NIH Striving to Avoid False Hope in Chronic Fatigue
January 23, 2018 - ClinicalTrials.gov: Occupational Stress
January 23, 2018 - PrEP could make US easily hit its 2020 HIV prevention goal, study finds
Scientists exploit leaks in blood brain barrier to treat glioblastoma

Scientists exploit leaks in blood brain barrier to treat glioblastoma

image_pdfDownload PDFimage_print

An ovarian cancer drug can leak through the blood brain barrier to reach brain tumours and could be an effective treatment for glioblastoma, suggest results presented at the National Cancer Research Institute’s (NCRI) Cancer Conference in Liverpool, today (Monday).

The Cancer Research UK-funded OPARATIC trial, which was managed by the charity’s Centre for Drug Development, tested whether the ovarian cancer drug olaparib could reach glioblastoma, a type of brain tumour which is very difficult to treat. And early results show it successfully reaches brain tumours at high enough levels for treatment.

The successful delivery of this drug is an important step as many others have failed to reach the tumour.

The study recruited 48 patients with glioblastoma which had returned after initial treatment. The majority of patients were then given olaparib in combination with the chemotherapy drug temozolomide.

Scientists looked at tumour samples and found that the drug penetrates the core of the tumour as well as the surrounding areas which contain smaller numbers of cancerous cells. Cancer cells in these regions cannot be removed by surgery so reaching them with drugs is crucial.

The researchers also identified a way to safely combine both drugs by giving olaparib intermittently, minimising dangerous side effects.

Olaparib is a PARP inhibitor, which is already used to treat certain ovarian cancer patients and prevents damaged cancer cells from repairing themselves after chemotherapy or radiotherapy.

The OPARATIC trial has paved the way for two additional clinical trials – PARADIGM and PARADIGM-2 – testing olaparib in combination with radiotherapy and temozolomide in patients with newly diagnosed glioblastoma.

Professor Anthony Chalmers, lead researcher and Chair of Clinical Oncology at the University of Glasgow, said: “Brain tumours are stubbornly difficult to treat and one of the main reasons for this is the blood brain barrier, a natural filter that blocks the passage of drugs.

“But these results suggest that olaparib is able to leak through because this barrier is disrupted in glioblastoma. By showing that this drug reaches brain tumours, we are in a much stronger position to use it to make current treatments more effective.”

Dr Nigel Blackburn, Cancer Research UK’s director of drug development, said: “While overall survival for cancer is improving, survival for brain tumours is still very low and the blood brain barrier is a significant pharmacological obstacle.

“Experimental trials like this, which test new ways to reach these hard to treat tumours, are crucially important if we are to see more patients survive their cancer.”

Professor Susan Short, member of NCRI’s Radiotherapy Research Working Group, said: “We’re just beginning to realise the full potential of PARP inhibitors to tackle many different types of cancer, so it’s exciting to see that olaparib could potentially be used to treat glioblastoma in combination with chemotherapy and radiotherapy.

“These results are a huge step forwards in developing better treatments for patients with brain tumours, which claim too many lives every year.”


Explore further:
Pancreatic cancer trial to make tumours more sensitive to treatment

Provided by:
Cancer Research UK

Tagged with:

About author

Related Articles